

Starpharma Holdings Ltd (SPL) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/S357E7E0B41EN.html>

Date: October 2021

Pages: 50

Price: US\$ 125.00 (Single User License)

ID: S357E7E0B41EN

Abstracts

Starpharma Holdings Ltd (SPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Starpharma Holdings Ltd (Starpharma) is a biotechnology company, which researches, develops and manufactures dendrimer products for pharmaceutical, life sciences and other applications. Dendrimers are synthetic nanoscale polymers with pharmaceutical and medical uses. The company's development programs include its DEP drug delivery, which is built around dendrimers and VivaGel portfolio. Its flagship product candidate, VivaGel, is a gel-based formulation for the treatment and prevention of bacterial vaginosis (BV) and it is also used as a vaginal microbicide to prevent sexually transmitted infections including HIV and genital herpes. It has license arrangements with several partners including Okamoto Industries and AstraZeneca among others. The company has research facilities in Melbourne, Australia. Starpharma is headquartered in Abbotsford, Victoria, Australia.

Starpharma Holdings Ltd Key Recent Developments

Jul 28,2021: Starpharma : Lynda Cheng appointed as non-executive director

Jul 27,2021: Starpharma to present DEP platform at CRS Annual Meeting

May 11,2021: VIRALEZE partners with Harlequins in the UK

Nov 20,2020: Starpharma: Retirement of non-executive director Richard Hazleton

Oct 30,2020: Starpharma: Quarterly cashflow and activities report

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Starpharma Holdings Ltd - Key Facts
Starpharma Holdings Ltd - Key Employees
Starpharma Holdings Ltd - Key Employee Biographies
Starpharma Holdings Ltd - Major Products and Services
Starpharma Holdings Ltd - History
Starpharma Holdings Ltd - Company Statement
Starpharma Holdings Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Starpharma Holdings Ltd - Business Description
Other Break-up: Interest Revenue
Performance
Other Break-up: Other Income
Performance
Other Break-up: Revenue from contracts with customers
Performance
Starpharma Holdings Ltd - SWOT Analysis
SWOT Analysis - Overview
Starpharma Holdings Ltd - Strengths
Starpharma Holdings Ltd - Weaknesses
Starpharma Holdings Ltd - Opportunities
Starpharma Holdings Ltd - Threats
Starpharma Holdings Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Starpharma Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Starpharma Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Starpharma Holdings Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 28, 2021: Starpharma : Lynda Cheng appointed as non-executive director

Jul 27, 2021: Starpharma to present DEP platform at CRS Annual Meeting

May 11, 2021: VIRALEZE partners with Harlequins in the UK

Nov 20, 2020: Starpharma: Retirement of non-executive director Richard Hazleton

Oct 30, 2020: Starpharma: Quarterly cashflow and activities report

Oct 21, 2020: Starpharma receives \$5.7M R&D tax incentive refund

Aug 17, 2020: Starpharma signs new DEP partnership with Chase Sun

Jul 30, 2020: Quarterly Cashflow and Activities Report

Mar 02, 2020: Starpharma appoints David McIntyre

Jan 29, 2020: Starpharma: Announces quarterly cashflow report

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Starpharma Holdings Ltd, Key Facts
Starpharma Holdings Ltd, Key Employees
Starpharma Holdings Ltd, Key Employee Biographies
Starpharma Holdings Ltd, Major Products and Services
Starpharma Holdings Ltd, History
Starpharma Holdings Ltd, Subsidiaries
Starpharma Holdings Ltd, Key Competitors
Starpharma Holdings Ltd, Ratios based on current share price
Starpharma Holdings Ltd, Annual Ratios
Starpharma Holdings Ltd, Annual Ratios (Cont...1)
Starpharma Holdings Ltd, Annual Ratios (Cont...2)
Starpharma Holdings Ltd, Interim Ratios
Starpharma Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Starpharma Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Starpharma Holdings Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Starpharma Holdings Ltd, Performance Chart (2017 - 2021)

Starpharma Holdings Ltd, Ratio Charts

Starpharma Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Starpharma Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Starpharma Holdings Ltd (SPL) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/S357E7E0B41EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S357E7E0B41EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970